On the morning of May 11th, Professor Li Xiaokun, President of Wenzhou Medical University (WMU) was honored with the “Outstanding Contribution Award for Translational Medicine” on “The 2nd Translational Medicine Awards Ceremony and National Major Science and Technology Infrastructure Alliance of Translational Medicine Conference” held at the International Academic Exchange Center of Sichuan University.
Two titles of “Outstanding Contribution Award for Translational Medicine” and five titles of “Innovation Award for Translational Medicine” were handed out on the Conference for this year. Chen Zhu, deputy chairman of the National People’s Congress and an academician of the Chinese Academy of Sciences, presented honorary certificates to two winners of “Outstanding Contribution Award for Translational Medicine”.
As a pioneer and leader in the research of growth factor genetic engineering drugs in China, Professor Li Xiaokun has pioneered the development of three new national Class One FGF family drugs with independent intellectual property rights, providing innovative drugs with active repair capabilities for the treatment of severe trauma and refractory ulcers. As of 2018, the FGFs series of drugs have been used in 5,500 hospitals across the country with a cumulative treatment of more than 68 million patients, establishing an international reputation and status for the industrialization of China’s cell growth factor drugs.
The Translational Medicine Award, formally known as “Translational Medicine Award Scheme”, is initiated by the Shanghai Guangci Translational Medicine Research and Development Foundation under the guidance of the National Major Science and Technology Infrastructure Alliance of Translational Medicine.The Award is to reward experts and scholars who have made outstanding contributions as well as clinicians and researchers who have achieved breakthrough innovations in translational medicine to motivate and train outstanding talents in the field of translational medicine.